ClinicalTrials.gg
CompletedNCT07052136Updated Jul 4, 2025

Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus

An interventional study of Levetiracetam and Valproic acid in Status Epilepticus, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing levetiracetam in Status Epilepticus — 2 open to participants now, 2 under way, 1 of them phase 3. Levetiracetam · Status Epilepticus.

Enrollment
7th of 13
138 · median 138
Started
2024
the only one that year
No phase
4 of 13
1 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
RESnTEC, Institute of Research

Among the 13 studies testing levetiracetam in Status Epilepticus, this one is the 7th largest by enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 11th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

2 of the 13 studies testing levetiracetam in Status Epilepticus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing levetiracetam in Status Epilepticus, or all of them as a file.
02

Study summary

Since there is a significant degree of variability in the results of previous studies and there exists a thirst for local data regarding this topic, the current study was planned, with the objective of comparing the efficacy of levetiracetam versus valproic acid in pediatric patients with status epilepticus.

Read the detailed description

Early and sustained control of seizures is paramount in status epilepticus to save the life of the patient, and this warrants the use of the best drug based on evidence. Identifying a better drug in status epilepticus would add to the local data and help clinicians in making evidence-based decisions to opt for an appropriate treatment in case of failed response to benzodiazepines.

03

Conditions studied

  • Status Epilepticus

Browse trials for

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any gender
  • Aged 2-14 years
  • Presenting with status epilepticus

Exclusion criteria

Exclusion Criteria:

  • Patients with focal seizures
  • Patients already using valproic acid or levetiracetam
  • Patients with a history of to either drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Levetiracetam group

    In this group, patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.

    Drug: Levetiracetam

  • Experimental
    Valproic acid group

    Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.

    Drug: Valproic acid

Interventions

  • Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.

  • Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.

06

What researchers measure

Primary outcomes

  1. Sustained control of seizure activity

    Sustained control was labeled when there was no seizure activity on EEG and regain of consciousness for ≥ 24 hours

    Time frame: 24 hours

Secondary outcomes

  1. Immediate cessation of seizure activity

    Immediate cessation was defined as cessation of seizure activity within 15-30 minutes, after completion of drug infusion.

    Time frame: 30 minutes

07

Study locations

1 site
  • Nishtar University Hospital
    Multan, Punjab Province 66000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2025, 5 months.

Of 22 interventional studies with no phase under Status Epilepticus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 65. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Nov 1, 2024
Primary completionActual
Apr 30, 2025
CompletionActual
Apr 30, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052136
Lead sponsor
RESnTEC, Institute of Research
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Nov 1, 2024
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025
Last update
Jul 4, 2025

Study contacts

Atifa Mazhar
principal investigator · Nishtar University Hospital, Multan
Javaria Rasheed, FCPS
study director · Nishtar University Hospital, Multan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levetiracetam · Valproic Acid

Start the discussion